Prostate Cancer News

News

Intermittent, Intensified Androgen Deprivation Therapy Provided PSA Survival Benefit for Patients With High-Risk Biochemically Relapsed Prostate Cancer

02/23/2024

Allison Casey

According to interim results from a phase 3 study, the addition of apalutamide to androgen deprivation therapy showed a statistically and clinically significant improvement of PSA progression-free survival among patients with high-risk...

According to interim results...

02/23/2024

Oncology

News

A Look at the Updates in the NCCN Clinical Practice Guidelines For Prostate Cancer

02/09/2024

Emry Lloyd ;

Get a summary of the changes in the NCCN guidelines regarding radiopharmaceuticals, secondary hormone therapy, and treatments for metastatic castration-sensitive prostate cancer.

Get a summary of the changes in...

02/09/2024

Journal of Clinical Pathways

Conference Coverage

Cabozantinib Plus Atezolizumab Significantly Prolonged PFS in Metastatic Castration-Resistant Prostate Cancer

01/25/2024

Stephanie Holland ;

Results from the ongoing phase 3 CONTACT-2 trial demonstrated that cabozantinib plus atezolizumab significantly improved rPFS compared to abiraterone plus prednisone or enzalutamide among patients with metastatic castration-resistant prostate...

Results from the ongoing phase 3...

01/25/2024

Oncology

News

Real-World Data Shows Benefit of Triplet Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

01/05/2024

Allison Casey ;

A real world study found triplet therapy to be an effective and tolerable treatment option for patients with metastatic hormone-sensitive prostate cancer.

A real world study found triplet...

01/05/2024

Oncology

News

Real-World Outcomes of EBRT Treatment for Patients With Localized Prostate Cancer

03/03/2023

Grace Taylor , MS, MA;

At the 2023 ASCO GU Cancers Symposium, Lawrence Karsh, MD, and colleagues presented data on real-world outcomes for using external beam radiation therapy to treat patients with high-risk localized prostate cancer (LPC) and...

At the 2023 ASCO GU Cancers...

03/03/2023

Journal of Clinical Pathways

News

Health Care Resource Utilization and Costs Associated With Disease Progression Among Patients With Metastatic Castration-Sensitive Prostate Cancer

06/09/2022

Ellen Kurek ;

Study results show direct all-cause health care costs in patients with nmCSPC often rose several months prior to diagnosis with metastatic disease.

Study results show direct...

06/09/2022

Journal of Clinical Pathways

News

In Patients With Unfavorable Intermediate-Risk Prostate Cancer, Brachytherapy Improved Overall Survival Compared with External-Beam Radiotherapy

05/18/2022

Ellen Kurek ;

Researchers reviewed the National Cancer Database records of nearly 32,000 men diagnosed with UIR prostate cancer to determine if men treated with brachytherapy had rates of survival comparable with those of men treated with EBRT.

Researchers reviewed the...

05/18/2022

Journal of Clinical Pathways

News

Comparing Costs and Health Care Resource Utilization Among Patients With Metastatic, Castration-Resistant vs Nonmetastatic Prostate Cancer

04/19/2022

Ellen Kurek ;

Findings from a retrospective cohort study suggest that patients with metastatic, castration-resistant prostate cancer experience higher costs, and require more outpatient services, compared with those with nonmetastatic cancer.

Findings from a retrospective...

04/19/2022

Journal of Clinical Pathways

News

Health Care Costs and Utilization Associated With Open vs Robotic-Assisted Radical Prostatectomy

02/22/2022

Janelle Bradley ;

Study findings suggest that lower postdischarge health care utilization after robotic-assisted prostatectomy may offset the higher costs during the index hospitalization.

Study findings suggest that...

02/22/2022

Journal of Clinical Pathways

News

Systematic Review Highlights Complexity of Cost-Effectiveness Models in Prostate Cancer

02/22/2022

Janelle Bradley ;

This systematic review of cost-effectiveness literature for novel diagnostic methods in prostate cancer shows that most studies have found novel methods to be more cost-effective than standard of care.

This systematic review of...

02/22/2022

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

$Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma$

Special Report

Clinical Pathways Updates in Multiple Myeloma: New and Expected Treatments for Refractory and Resistant Multiple Myeloma

01/14/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Prostate Cancer News

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products